^
    1d
    CD22 CAR T-cells to Extend Remission Following Commercial CD19 CAR T-cells in Children, Adolescents, and Adults With Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia (clinicaltrials.gov)
    P2, N=20, Recruiting, National Cancer Institute (NCI) | Not yet recruiting --> Recruiting
    Enrollment open
    |
    CD22 (CD22 Molecule)
    |
    cyclophosphamide • fludarabine IV
    1d
    Azacitidine and Abatacept in Relapsed or Refractory T-Cell Lymphoma (clinicaltrials.gov)
    P1, N=20, Suspended, National Cancer Institute (NCI) | Recruiting --> Suspended
    Trial suspension
    |
    azacitidine • Orencia (abatacept)
    1d
    A Multicenter RCT of "3+7" vs Venetoclax + CACAG in Newly Diagnosed Mid/High-Risk AML Patients (clinicaltrials.gov)
    P2, N=160, Recruiting, Chinese PLA General Hospital | Active, not recruiting --> Recruiting
    Enrollment open
    |
    Venclexta (venetoclax) • cytarabine • azacitidine • Epidaza (chidamide) • aclarubicin
    1d
    Targeted CD22/CD19 CAR-T Therapy for Consolidation in Standard-Risk B-ALL (clinicaltrials.gov)
    P1/2, N=20, Recruiting, Liping Dou
    New P1/2 trial
    |
    CD22 (CD22 Molecule)
    |
    CD19 positive • CD22 positive
    1d
    Exploratory Study of CD22/CD19 Dual-Target CAR-T Cell Therapy as Consolidation Treatment After First Remission in High-Risk B-Cell Acute Lymphoblastic Leukemia (clinicaltrials.gov)
    P1/2, N=30, Recruiting, Liping Dou
    New P1/2 trial
    |
    CD22 (CD22 Molecule)
    |
    CD19 positive • CD22 positive
    1d
    A Study of JNJ-89853413 for Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Neoplasms (clinicaltrials.gov)
    P1, N=64, Active, not recruiting, Janssen Research & Development, LLC | Recruiting --> Active, not recruiting | N=115 --> 64
    Enrollment closed • Enrollment change • First-in-human
    1d
    Proteomic and phosphoproteomic signatures of disease progression in unmutated IGHV chronic lymphocytic leukemia. (PubMed, Clin Proteomics)
    Specific proteins and phosphopeptides identified here, upon further validation, may serve as biomarkers for early intervention in UM‑CLL. More broadly, our study demonstrates the value of integrated proteomic and phosphoproteomic profiling which may lead to refining risk stratification and advancing understanding of the complex biology underlying CLL progression.
    Journal
    |
    IGH (Immunoglobulin Heavy Locus)
    |
    IGH mutation
    1d
    WT1 mRNA in peripheral blood enables early prognostic stratification in AML patients receiving venetoclax and azacitidine therapy. (PubMed, Ann Hematol)
    Moreover, achieving PB WT1 mRNA negativity-regardless of whether this occurred early or later in the therapy།was consistently associated with superior OS and PFS. These findings suggest that PB WT1 mRNA is a sensitive and reliable biomarker for predicting treatment response and long-term outcomes in patients with AML receiving VEN/AZA.
    Journal • IO biomarker
    |
    BCL2 (B-cell CLL/lymphoma 2) • WT1 (WT1 Transcription Factor)
    |
    Venclexta (venetoclax) • azacitidine
    1d
    The impact of gene polymorphisms on the response of methotrexate-based treatments. (PubMed, Eur J Clin Pharmacol)
    Although considerable research has been conducted and numerous results have been obtained, the available evidence remains predominantly of moderate quality. Consequently, current guidelines from CPIC and the DPWG do not recommend routine MTX dose adjustments based solely on single gene variants. It is, therefore, imperative to develop and validate multifactorial risk prediction tools that integrate a range of other clinical factors. Accordingly, the establishment of a comprehensive pharmacogenetics-guided dosing guideline for MTX remains an elusive goal.
    Review • Journal
    |
    TYMS (Thymidylate Synthetase) • MTHFR (Methylenetetrahydrofolate Reductase)
    |
    methotrexate
    1d
    CRISPR base editor screening identifies spectrum of MEN1 mutations impacting menin inhibitors in clinical trials. (PubMed, Nat Commun)
    CRISPR base editor screening previously predicted several MEN1 (menin) mutations that have arisen in patients receiving SNDX-5613 and confer resistance...Co-crystal structures of menin bound to each menin inhibitor suggest resistance mechanisms related to how each inhibitor engages the KMT2A binding pocket of menin. Orthogonal in vitro and in vivo MEN1 mutation generation under therapeutic pressure suggest the MEN1 mutations identified with CRISPR base editor screening are likely to arise and impact all menin inhibitors.
    Journal
    |
    NPM1 (Nucleophosmin 1) • KMT2A (Lysine Methyltransferase 2A) • MEN1 (Menin 1)
    |
    NPM1 mutation
    |
    Revuforj (revumenib)
    1d
    Transcript distribution, sequence characteristics and clinical outcomes of rare transcript types of BCR::ABL1 fusion gene-positive leukemia patients (PubMed, Zhonghua Yi Xue Za Zhi)
    The splicing variations mainly occur in ABL1 exon 3 or different exons of BCR, and some are accompanied by intron sequence insertions. Patients with e13a3 type of rare transcripts respond well to TKI treatment, while patients with the e1a3 and e19a2 have poor prognosis.
    Clinical data • Retrospective data • Journal
    |
    ABL1 (ABL proto-oncogene 1)
    |
    ABL1 fusion
    1d
    Clinical characteristics and prognostic analysis of acute erythroid leukemia (PubMed, Zhonghua Nei Ke Za Zhi)
    Survival differed significantly among the three etiological groups (χ2=11.53, P=0.003). AEL is a subtype of acute myeloid leukemia with extremely poor prognosis that is highly associated with TP53 gene abnormalities.
    Retrospective data • Journal
    |
    TP53 (Tumor protein P53)
    |
    TP53 mutation • TP53 deletion